Abstract
BackgroundMethotrexate (MTX) is the DMARD of choice in the treatment of rheumatoid arthritis (RA). There is important variability in its therapeutic response. The identification of genetic factors related to the...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have